Results from the study will be included in Eurand’s new drug application (NDA) for Zentase. Eurand initiated its rolling NDA submission in June 2007 and has been granted Fast Track designation by the FDA.
Gearoid Faherty, CEO, said: “The completion of this study will allow us to complete our NDA submission for Zentase before the end of the year as planned.”